Investigational drug · Phase 2
Nazartinib
Also called: EGF816
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Solid Tumors Which Are cMET-dependent.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
10
Any phase or sponsor naming "Nazartinib"
First trial start
2017
Jul 4, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Nazartinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors Which Are cMET-dependent
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Nazartinib" as an intervention, largest first.
Novartis PharmaceuticalsNovartis (NVS)
NCT02900664 · 283 participants · Start Aug 23, 2016 · Primary completion Mar 17, 2021
Drug: PDR001; ACZ885 and 3 more · For: Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Sites: Baltimore, Maryland; Boston, Massachusetts; Nashville, Tennessee · 23 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT03114319 · 227 participants · Start May 26, 2017 · Primary completion Jul 4, 2025
Drug: TNO155; TNO155 in combination with EGF816 (nazartinib) · For: Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC); KRAS G12-mutant NSCLC; Esophageal Squamous Cell Cancer (SCC) and 4 more
Sites: Tampa, Florida; Boston, Massachusetts; New York, New York · 18 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT02108964 · 225 participants · Start Jun 6, 2014 · Primary completion Mar 22, 2018
Drug: EGF816 · For: Advanced Non-small Cell Lung Cancer
Sites: Boston, Massachusetts; New York, New York; Toronto, Canada · 14 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT02335944 · 177 participants · Start Jan 13, 2015 · Primary completion Nov 10, 2020
Drug: Capmatinib; Nazartinib · For: Non Small Cell Lung Cancer
Sites: Boston, Massachusetts; Melbourne, Australia; Edmonton, Canada · 19 sites in all
- Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT03333343 · 105 participants · Start Jan 29, 2018 · Primary completion Jul 12, 2027
Drug: EGF816; trametinib and 4 more · For: EGFR-mutant Non-small Cell Lung Cancer
Sites: Toronto, Canada; Cologne, Germany; Essen, Germany · 11 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT02323126 · 64 participants · Start Feb 9, 2015 · Primary completion Sep 23, 2019
Drug: EGF816; INC280 and 1 more · For: Non Small Cell Lung Cancer
Sites: Houston, Texas; Camperdown, Australia; Chermside, Australia · 13 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT03040973 · 29 participants · Start Jul 4, 2017 · Primary completion Jul 30, 2027
Drug: Capmatinib; Nazartinib and 2 more · For: Advanced Solid Tumors Which Are cMET-dependent
Sites: Boston, Massachusetts; Leuven, Belgium; Edmonton, Canada · 15 sites in all
University of CologneAcademic, hospital or other
NCT03516214 · 18 participants · Start Apr 25, 2018 · Primary completion Sep 30, 2022
Drug: EGF816; Trametinib · For: Bronchial Neoplasms
Sites: Cologne, Germany; Dresden, Germany; Essen, Germany · 7 sites in all
Massachusetts General HospitalAcademic, hospital or other
NCT03292133 · 11 participants · Start Oct 31, 2017 · Primary completion Dec 31, 2021
Drug: EGF816; Gefitinib · For: Lung Cancer
Sites: Boston, Massachusetts
- Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating MutationsPivotal-lookingWithdrawn
Novartis PharmaceuticalsNovartis (NVS)
NCT03529084 · 0 participants · Start Jul 24, 2018 · Primary completion Aug 13, 2020
Drug: EFG816; erlotinib or gefitinib · For: Carcinoma, Non-small Cell Lung
Newest research
PubMed records naming it or its code names, newest first.
- Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.
Felip E, Metro G, Soo RA, et al. · Eur J Cancer 2024
- Characterization of the in vitro metabolic profile of nazartinib in HLMs using UPLC-MS/MS method: In silico metabolic lability and DEREK structural alerts screening using StarDrop software.
Attwa MW, Abdelhameed AS, Kadi AA · Heliyon 2024
- Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.
Tiedt R, King FJ, Stamm C, et al. · Cell Rep 2023
- Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.
Tan DSW, Kim SW, Ponce Aix S, et al. · Eur J Cancer 2022
- Studies on ligand-based pharmacophore modeling approach in identifying potent future EGFR inhibitors.
Shaikh GM, Murahari M, Thakur S, et al. · J Mol Graph Model 2022
- New C2- and N3-Modified Thieno[2,3-d]Pyrimidine Conjugates with Cytotoxicity in the Nanomolar Range.
Mavrova AT, Dimov S, Yancheva D, et al. · Anticancer Agents Med Chem 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.